DaVita (DVA) Tops Q2 EPS by 3c

DaVita (NYSE: DVA) reported Q2 EPS of $1.01, $0.03 better than the analyst estimate of $0.98. Revenue for the quarter came in at $3.72 billion versus the consensus estimate of $3.67 billion.

• We are updating our adjusted consolidated operating income guidance for 2016 to be in the range of $1.785 billion to $1.875 billion.Our previous adjusted consolidated operating income guidance for 2016 was in the range of $1.800 billion to $1.950 billion.
• We are updating our operating income guidance for Kidney Care for 2016 to be in the range of $1.675 billion to $1.725 billion.Our previous operating income guidance for Kidney Care for 2016 was in the range of $1.625 billion to $1.725 billion.
• We are updating our adjusted operating income guidance for HCP for 2016 to be in the range of $110 million to $150 million.Our previous adjusted operating income guidance for HCP for 2016 was in the range of $175 million to $225 million.
• We are updating our consolidated operating cash flow for 2016 to be in the range of $1.600 billion to $1.750 billion.Our previous consolidated operating cash flow for 2016 was in the range of $1.550 billion to $1.750 billion.

For earnings history and earnings-related data on DaVita (DVA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance